Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Articles by Saag KG, Wagman RB, Geusens P, et al. Denosumab versus risedronate in glucocorticoid-induced osteoporosis: a multicentre, randomised, double-blind, active-controlled, double-dummy, non-inferiority study. Lancet Diabetes Endocrinol. 2018, 6(6):445-454. doi: 10.1016/S2213-8587(18)30075-5.
Advertisement
Latest Updated Articles
- Study Summary: Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis
Published: August 13th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
CAR T-Cell Therapy Holds Potential in SCLC, but Significant Barriers Remain
2
Value-Based Care Interventions and Management of CKD Progression
3
New Partnership Model Boosts Maternal Outcomes in Medicaid ACOs
4
CDC Reports Largest Pediatric Influenza-Associated Encephalopathy Case Series in 2024-2025 Season
5
